Citigroup Maintains Buy on ArriVent BioPharma, Raises Price Target to $33
Citigroup analyst Yigal Nochomovitz maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and raises the price target from $31 to $33.
Login to comment